Uppsala,
Dicot, currently in the clinical phase with its potency drug candidate LIB-01, is in an expansive phase aiming to develop a new generation of potency drugs for a global market. As part of the upgrade to a larger pharmaceutical company, the company's Annual General Meeting on
Today, the name change has been registered by the Swedish Companies Registration Office, formally implementing the change. The company's official website and email addresses will soon transition from dicot.se to dicotpharma.com as part of the ongoing process work of the name change.
The share name will change from Dicot to Dicot Pharma. The last day of trading in the share in the current name is
"We are gradually expanding into a larger pharmaceutical company as our results from clinical studies emerge. Strengthening and internationalizing profiling is part of that expansion. The addition "Pharma" is logical and will support us in this process," says
For further information, please contact:
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicot.se
About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at
Dicot is listed on
https://news.cision.com/dicot-ab--publ-/r/today-dicot-ab-becomes-dicot-pharma-ab,c3992207
https://mb.cision.com/Main/17172/3992207/2835331.pdf
(c) 2024 Cision. All rights reserved., source